SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Sales for the quarter ended March 2026 of Rs. 38220.00 million declined by -31.29% from Rs. 55629.00 millions.The Net Loss for the quarter ended March 2026 is Rs. -2194.00 millions as compared to Net Profit of Rs. 12007.00 millions of corresponding quarter ended March 2025A decline of 673.00 millions was observed in the OP in the quarter ended March 2026 from 18574.00 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 38220.00 55629.00 -31.29 205328.00 231154.00 -11.17 205328.00 231154.00 -11.17
Other Income 5672.00 4144.00 36.87 16896.00 10034.00 68.39 16896.00 10034.00 68.39
PBIDT 673.00 18574.00 -96.38 56070.00 83852.00 -33.13 56070.00 83852.00 -33.13
Interest 543.00 311.00 74.60 1483.00 1099.00 34.94 1483.00 1099.00 34.94
PBDT 130.00 18263.00 -99.29 54587.00 82753.00 -34.04 54587.00 82753.00 -34.04
Depreciation 3185.00 2645.00 20.42 12074.00 10394.00 16.16 12074.00 10394.00 16.16
PBT -3055.00 15618.00 -119.56 42513.00 72359.00 -41.25 42513.00 72359.00 -41.25
TAX -861.00 3611.00 -123.84 10316.00 18865.00 -45.32 10316.00 18865.00 -45.32
Deferred Tax 286.00 -32.00 -993.75 1139.00 960.00 18.65 1139.00 960.00 18.65
PAT -2194.00 12007.00 -118.27 32197.00 53494.00 -39.81 32197.00 53494.00 -39.81
Equity 835.00 834.00 0.12 835.00 834.00 0.12 835.00 834.00 0.12
PBIDTM(%) 1.76 33.39 -94.73 27.31 36.28 -24.72 27.31 36.28 -24.72

Dr. Reddys Lab Share Price

1267.05 4.40 (0.35%)
04-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.35
Dr. Reddys Lab 1267.05
Cipla 1397.75
Zydus Lifesciences 1085.45
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×